Skin Clearance and Itch Relief in Black or African American Patients with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib: 140-Week Outcomes from Integrated Phase 3 Measure Up 1 and 2 Studies. J of Skin. 2025;9(6):s615. doi:10.25251/9qs79351